TAVALISSE

This brand name is authorized in Canada, Israel, Japan, United States

Active ingredients

The drug TAVALISSE contains one active pharmaceutical ingredient (API):

1 Fostamatinib UNII SQ8A3S5101 - FOSTAMATINIB

Fostamatinib mediates its activity effectively through its major metabolite, R406, which is a tyrosine kinase inhibitor with demonstrated activity against spleen tyrosine kinase (SYK). R406 inhibits signal transduction of B-cell receptors and Fc-activating receptors, which play a key role in antibody-mediated cellular responses. The fostamatinib metabolite R406 reduces antibody-mediated destruction of platelets. Read about Fostamatinib

Medication package inserts

Below package inserts are available for further reading:

Title	Information Source	Document Type
TAVALISSE Film-coated tablet	FDA, National Drug Code (US)	MPI, US: SPL/PLR

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC code	Group title	Classification
B02BX09		B Blood and blood forming organs → B02 Antihemorrhagics → B02B Vitamin K and other hemostatics → B02BX Other systemic hemostatics
Discover more medicines within B02BX09

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
Country: CA	Health Products and Food Branch	Identifier(s): 02508052, 02508060
Country: IL	מִשְׂרַד הַבְּרִיאוּת	Identifier(s): 8792, 8793
Country: JP	医薬品医療機器総合機構	Identifier(s): 3999058F1026, 3999058F2022
Country: US	FDA, National Drug Code	Identifier(s): 71332-001, 71332-002